Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.agios.com
Agios Pharmaceuticals, Inc. News Releases
Get the latest updates from Agios Pharmaceuticals, Inc. News Releases directly as they happen.
Follow now 36 followers
Latest posts
Last updated 5 days ago
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
5 days ago
CAMBRIDGE, Mass. , May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
12 days ago
CAMBRIDGE, Mass. , May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
13 days ago
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ®...
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
27 days ago
CAMBRIDGE, Mass. , April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
2 months ago
CAMBRIDGE, Mass. , March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios to Present at Upcoming Investor Conferences
2 months ago
CAMBRIDGE, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
3 months ago
CAMBRIDGE, Mass. , Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
3 months ago
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
3 months ago
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral...
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
3 months ago
CAMBRIDGE, Mass. , Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
4 months ago
– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND ® (mitapivat)...
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
4 months ago
CAMBRIDGE, Mass. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc...